Humanoid robotics: Humanoid capacity is scaling quickly, but adoption conversion and regulation remain near-term constraints

Overview

This UBS thematic update examines whether accelerating humanoid-robot capacity is translating into commercial adoption. Its China and Europe executive surveys support a constructive long-term demand outlook, but UBS stresses that deployment, affordability, intelligence and regulatory clarity remain the immediate gating factors.

Core views

UBS observes a continued shift from humanoid prototypes toward production deployment worldwide, although the robot “brain” remains the principal technological bottleneck. In China, UBTECH’s Liuzhou factory with planned annual capacity above 10,000 units entered production, XPeng began operating an automated humanoid assembly line, and reducer producers Leader Drive and Laifu are pursuing capacity expansion. Overseas momentum also includes OpenAI’s return to humanoids, Figure AI’s access to up to 100,000 NVIDIA GPUs, Toyota’s wheeled humanoid ELEY, and reports that Toyota plans to deploy 400,000 robots—humanoid and non-humanoid—across manufacturing and supplier facilities from 2028. UBS’s China channel checks also point to a gradual production ramp among Tesla Optimus suppliers. The report argues that tougher oversight creates short-term pressure but could improve industry quality over time. Potentially stricter China IPO scrutiny and questions over start-up revenue quality have hurt sentiment; UBS expects higher standards to promote consolidation and more sustainable growth. In the US, the FCC announced restrictions on certain foreign-made advanced robotic systems, including humanoids and quadrupeds, on July 28. Exemptions require credible US localization and supply-chain compliance plans. UBS believes this could limit Chinese robot OEMs’ US market access, while near-term effects on component suppliers should be limited because the restrictions chiefly target finished systems. Survey evidence indicates that China is ahead of Europe in willingness and deployment, while actual conversion remains incomplete. In UBS Evidence Lab’s June 2026 China survey, 64% of respondents would consider humanoids to replace labor and 45% were already testing them on production lines, compared with 51% and 38%, respectively, in the May 2026 Europe survey. UBS estimates China is roughly one to two years ahead in commercialization and deployment. Yet China’s production-line testing rate has not expanded over two years, falling to 45% in June 2026 from 57% in May 2024, and deployment has generally moved with adoption intent. Cost remains a key purchase barrier, and UBS identifies repeat orders and capacity utilization as the crucial near-term evidence that new production capacity is being absorbed. UBS nevertheless sees long-term demand signals as intact. China adoption intent has remained above 50% in all five survey waves and reached 64% in June 2026; 93% of respondents expect humanoid robots to be commercialized within five years. Willingness to pay also improved: 36% would pay more than Rmb400,000 per unit, compared with 24% in May 2024, while safety concerns among non-considering companies have eased. UBS expects capacity expansion and lower costs to narrow the gap between current pricing and customers’ willingness to pay. It emphasizes multi-wave trends rather than changes in the latest China wave because the June 2026 sample was relatively small. Across regions, technology and consumer-goods manufacturing, including autos, rank above average in adoption intent. China has greater interest in sorting, consistent with its manufacturing scale and automation demand, while both China and Europe expect assembly applications to expand. As assembly requires capabilities beyond the material-handling tasks dominating many current pilots, UBS concludes that dexterity and AI progress are essential for broader adoption. European firms expect a narrower application set than Chinese firms, but in both regions assembly is cited at least as often as loading and unloading. UBS upgraded its 2026-30 global humanoid demand forecasts by more than 70% annually, reflecting faster anticipated adoption in preparatory and lower-complexity applications. It also forecasts 2025-30 China demand CAGRs of 10-60% across traditional robot categories, with AI serving as a broader robotics catalyst. Despite these demand expectations, UBS says sentiment is unlikely to improve materially until Tesla Optimus V3 mass-production plans, AI-model generalisation and hardware advances are clearer. It therefore prefers upstream components serving multiple robot OEM categories—especially sensors, reducers and roller screws—because of their market size and technological barriers, and names OPT, Kedali and Hengli Hydraulic as China top picks.

Analysis framework

UBS combines global production and policy developments with multi-wave China and Europe C-suite survey data, comparing adoption intent, production-line testing, use cases, willingness to pay and barriers. It then links those demand indicators to supply-chain positioning and monitors market sentiment, Tesla Optimus production commentary and upcoming industry catalysts.

Methodology notes

• Industry AnalysisSupply-demand framework

  Humanoid supply expansion compared with adoption intent, testing, willingness to pay and eventual repeat orders.

  UBS uses capacity additions and survey demand indicators to assess whether production is outrunning current sales and what would support broader adoption.

• Industry AnalysisUpstream-Midstream-Downstream Transmission

  Robot OEM regulation and deployment are assessed alongside implications for upstream components.

  The report distinguishes finished-system exposure from component exposure and favors components that can supply multiple OEM categories.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• OPT Machine Vision (688686.SH)

  China top pick and sensor-related upstream component exposure.

  Strengths

  UBS favors sensors due to attractive market size and technological barriers.

  Comparison

  Preferred alongside Kedali and Hengli Hydraulic among UBS China top picks.

  Risks

  Downstream capacity expansion may disappoint; gross margin may weaken if in-house-product mix improves slowly or downstream mix deteriorates; SG&A may rise with new-business development.

• Shenzhen Kedali Industry (002850.SZ)

  China top pick and upstream component exposure.

  Strengths

  UBS identifies Kedali among its preferred China names.

  Comparison

  Preferred alongside OPT and Hengli Hydraulic.

  Risks

  Capacity ramps, major-customer expansion, market share and product quality may disappoint; EV penetration, battery-firm pricing pressure, competitor capacity, raw-material costs, vehicle demand and trade frictions are additional risks.

• Jiangsu Hengli Hydraulic (601100.SH)

  China top pick and component exposure.

  Strengths

  UBS identifies Hengli Hydraulic among its preferred China names.

  Comparison

  Preferred alongside OPT and Kedali.

  Risks

  Domestic excavator sales, pump and valve demand, overseas-brand supply-chain entry, non-standard-product demand and overseas expansion may fall short, including because of trade frictions.

Key data

• Global humanoid demand forecast revision>70% annuallyUBS upgraded its 2026-30 forecasts, citing faster adoption in preparatory and lower-complexity use cases.
• China adoption intent / production-line testing64% / 45%June 2026 UBS Evidence Lab survey.
• Europe adoption intent / production-line testing51% / 38%May 2026 UBS Evidence Lab survey.
• China respondents expecting commercialization within five years93%June 2026 survey.
• China respondents willing to pay more than Rmb400,000 per unit36%Up from 24% in May 2024.
• China traditional robot demand CAGR forecast10-60%UBS forecast for 2025-30 across robot categories.

Impact & implications

UBS sees a widening gap between expanding humanoid capacity and still-limited deployment, making proof of repeat orders and utilization central near-term indicators. Its preferred exposure is upstream components with broad OEM applicability, while clearer evidence on Tesla Optimus, AI intelligence and hardware progress is needed for a sustained sentiment recovery.

Risks

• New humanoid capacity may continue to outpace sales if repeat orders and utilization do not improve.
• Cost, insufficient robot intelligence and limited dexterity may delay broader deployment beyond current pilot applications.
• Tighter China IPO scrutiny could pressure sector sentiment in the near term.
• US restrictions on certain foreign-made advanced robotic systems could hinder Chinese OEM access to the US market.
• Weak Chinese macro conditions, reduced industrial investment, policy changes and intense competition could weigh on industrial demand and earnings.

What to watch

• Repeat orders and utilization at expanding humanoid production capacity.
• Tesla Optimus V3 mass-production progress, with Tesla expecting mass production by end-2026.
• Progress in AI model generalisation, dexterity and robot hardware.
• China IPO-review developments and implementation of US localization and supply-chain requirements.
• Upcoming industry events, Tesla Q3 2026 results and A-share humanoid-related third-quarter results.